Company intelligence / Profile preview
Biofrontera
Woburn, Massachusetts, United Statesbiofrontera-us.com ↗
- Ownership
- Public · BFRI
- Development stage
- Other
01
Overview
Biofrontera has commercial products including Ameluz (a topical prescription drug) and RhodoLED/RhodoLED XL (proprietary red-light lamps) for photodynamic therapy of actinic keratoses. The company reported record financial results for fiscal year 2024 and is conducting clinical trials to expand indications to include trunk and extremities, non-melanoma skin cancers, and acne.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Photodynamic therapy (PDT)Topical antibioticsNanoemulsion technology
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
LEO Pharma GmbHGerman Medical Engineering GmbH
04
Financials
- Market cap
- $12M
- Total revenue
- $41.7M
- Enterprise value
- $14.8M
Beyond the preview
Go deeper on Biofrontera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biofrontera.